HER2 Gene News and Research

RSS

The HER2 (human epidermal growth factor receptor 2) gene is part of a family of genes that play roles in regulating cell growth. The protein it makes is a tyrosine kinase growth factor receptor that a number of normal tissues express and which probably has a role in normal cell function, regulating growth and proliferation.

Tumors less than 1 centimeter in size can be aggressive and may require maximum therapy

Breast tumors that are 1 centimeter in size or smaller - no more than 0.4 inch in length - can still be very aggressive and may require more intensive therapy than is routinely offered today, say researchers at Mayo Clinic in Jacksonville, Fla.

17 Dec 2007

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

17 Dec 2007

Study shows how mutations in the BRCA1 gene lead to breast cancer

An international team of researchers led by Columbia University Medical Center's Herbert Irving Comprehensive Cancer Center and Sweden's Lund University has, for the first time, revealed how mutations in the BRCA1 gene lead to breast cancer.

10 Dec 2007

Two proteins may be survival markers in some breast cancers

New research suggests that the presence or absence of two proteins may be important markers for long-term survival in some breast-cancer patients.

13 Nov 2007

Bavarian Nordic updates on vaccine project pipeline

In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

6 Nov 2007

Osteopontin-c is a good biomarker of breast cancer.

Researchers have identified a molecule that may be more accurate than existing biological signposts used to predict which breast cancers will develop into advanced forms of the disease.

6 Nov 2007

New insight into Herceptin resistance in breast cancer

A new study provides important insight into the mechanisms involved in resistance to treatment of breast cancer patients with trastuzumab (Herceptin). The research, published by Cell Press in the October issue of the journal Cancer Cell , identifies markers that may help to identify patients who are unlikely to respond to trastuzumab treatment and provides a potential strategy for treating these patients.

16 Oct 2007

Trop-2 new target for anti-tumour therapy in cancer

Italian scientists announced (Monday September 24) that they have found a new and promising target for anti-tumour therapy in cancer.

25 Sep 2007

Impact of food-cancer drug interactions

A commentary in the Journal of Clinical Oncology (JCO) urges researchers to explore an intriguing approach to reduce the dose, and therefore the cost, of oral targeted cancer therapies.

18 Jul 2007

Scientists develop largest ever series of human breasts cancers grafted into mice

At the Institut Curie, Inserm researchers and physicians have established the largest ever panel of human breast cancer xenografts in animal models.

13 Jul 2007

African-Americans women more likely to present with later stage and higher grade breast cancer tumors compared to Caucasians

African-American women are diagnosed with more advanced breast cancer than Caucasians, according to a new, single hospital study.

10 Jul 2007

Breast cancers to be more aggressive in African-American women

A study of more than 2,200 women at the Kimmel Cancer Center at Jefferson in Philadelphia shows that African American women have more advanced breast cancer at the time of diagnosis than Caucasian women.

10 Jul 2007

Racial differences in severity of breast cancer presentation confirmed

African-American women are diagnosed with more advanced breast cancer than Caucasians, according to a new, single hospital study.

10 Jul 2007

Trastuzumab and chemo improves survival in women with operable HER-2 positive breast cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

9 Jul 2007

Novel method of drug delivery to inhibit the growth of prostate cancer cells

Prostate cancer is the second leading cause of cancer-related death for men in the U.S. Present treatments for metastatic prostate cancer (cancer cells that spread to other parts of the body) include hormonal therapy, chemotherapy and radiotherapy, which frequently have serious side effects.

23 Jun 2007

Newer breast cancer drug may protect heart

By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs.

16 Jun 2007

Herceptin does not increase heart failure in patients long-term

Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

5 Jun 2007

Drug lapatinib shows activity against brain metastases

The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical trial presented by Dana-Farber Cancer Institute scientists at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2007

Benefits of Herceptin are lasting

An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.

5 Jun 2007

Why cisplatin kills breast cancer cells when other drugs fail

The cancerous cells of some individuals with breast cancer lack expression of two cell surface proteins, the estrogen and progesterone receptors, and do not express increased amounts of HER2.

20 Apr 2007